Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Jenny Sauk

Description

Summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).

Official Title

A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

Keywords

Ulcerative Colitis, Colitis, Ulcer, Guselkumab, Induction Study 2: Guselkumab IV

Eligibility

Locations

  • UCLA
    Los Angeles California 90095 United States
  • Om Research LLC
    Lancaster California 93534 United States

Lead Scientist at UCLA

  • Jenny Sauk
    HS Associate Clinical Professor, Medicine. Authored (or co-authored) 64 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Janssen Research & Development, LLC
ID
NCT04033445
Phase
Phase 2/3 research study
Study Type
Interventional
Participants
About 1064 people participating
Last Updated